{"meshTagsMajor":["Breast Neoplasms"],"meshTags":["Prognosis","Mutation","Female","Receptors, Estrogen","Antineoplastic Agents","Breast Neoplasms","Survival Rate","Humans","Receptors, Progesterone","Receptor, ErbB-2","Genes, BRCA1"],"meshMinor":["Prognosis","Mutation","Female","Receptors, Estrogen","Antineoplastic Agents","Survival Rate","Humans","Receptors, Progesterone","Receptor, ErbB-2","Genes, BRCA1"],"genes":["estrogen receptor","progesterone receptor","HER2"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Review"],"abstract":"Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.","title":"Triple-negative breast cancer.","pubmedId":"21067385"}